Converge Bio Inc.
Last verified 2026-05-07. JSON
| Total raised | $25.0M |
|---|---|
| Latest round | Funding round, $25.0M, 2025-09-24 |
| Founded | 2024 |
| Headquarters | CLAYMONT, DE |
| Industry | biotechnology |
| Stage | unknown |
| Website | convergebio.com |
Converge Bio provides a generative AI platform that accelerates drug discovery, molecule design, and manufacturing optimization. It serves pharmaceutical and biotech teams shortening development cycles. Customer data stays private and is never shared or used for model training, keeping proprietary research under full customer control.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-09-24 | Funding round | $25.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $25.0M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Total raised $25.0M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Company existence | self-reported | convergebio.com, read 2026-05-07 |
| Description | self-reported | convergebio.com, read 2026-05-07 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $25.0M, 2025-09-24 → Funding round, $25.0M, 2025-09-24, SEC EDGAR, document, retrieved 2026-09-25 | Latest round | seed, $25.0M, 2025-09-24 → Funding round, $25.0M, 2025-09-24 | SEC EDGAR, document, retrieved 2026-09-25 |
| 2026-09-25Round: attributed → sourced, SEC EDGAR, document, retrieved 2026-09-25 | Round | attributed → sourced | SEC EDGAR, document, retrieved 2026-09-25 |
Records begin 2026-09-24. All changes